이탈리아의 심혈관 질환의 1 차 예방을위한 새로운 위험 예측 접근법 : CVRISK-IT 시험 (CVRISK-IT) (CVRISK-IT)
이탈리아의 심혈관 질환의 1 차 예방을위한 새로운 위험 예측 접근법 : CVRISK-IT 시험
The CVRISK-IT study aims to evaluate the health benefit of measuring genetic and imaging risk information in men and women considered at 'low-to-moderate' or 'high' risk of developing cardiovascular diseases (CVD) in a randomized controlled trial in Italian primary care settings. Our primary objective is to answer a fundamental question in the prevention and prediction of CVD in Italy and globally: is there any benefit in including additional information (such as genetic and/or imaging data) in estimating risk, in conjunction with lifestyle advice and medical treatment for primary prevention of CVD?
As a key secondary objective of the CVRISK-IT study, the goal is to build a large bioresource with clinical information and biological samples to facilitate a new generation of discovery and translational research that will advance understanding of the genetic, molecular and behavioural determinants as well as mechanisms of multiple chronic diseases in the Italian population. By contributing to the Rete Cardiologica database and the BBDCARDIO biobank, the CVRISK-IT study will also serve as a cornerstone for future investigations into the development and testing of early diagnostic technologies and preventive (or 'personalised precision health') interventions for chronic diseases.
연구 개요
상세 설명
This multicenter, open randomized trial will investigate the effects of providing additional CVD risk information alongside personalised lifestyle advice and medical treatment in a primary prevention context across Italy. Healthy individuals aged 40 to 80 years, with no prior history of CVD or diabetes, will be recruited in two phases from the cohort of 17 participating IRCCS across Italy and affiliated enrolling centers. The population enrolled in this study consists of subjects who have never participated in other cardiovascular prevention studies of the Rete Cardiologica.
Phase 1 - Identification of the study population and development of the bioresource: various recruitment sources will be used, including institutions, primary care centres/services, government agencies, occupational health services, and volunteer organizations (e.g., blood donors). Participants will provide informed consent, a blood sample, and complete an electronic questionnaire. Approximately 30,000 individuals will be recruited and assessed using SCORE2/SCORE2-OP risk prediction models. Those identified as 'very high' risk will receive immediate medical treatment and will not proceed to phase 2.
Phase 2 - Randomization and novel risk prediction interventions: Participants identified as 'low-to-moderate' or 'high' CVD risk during phase 1 will be randomized, following a 2x2 factorial design into four groups within 1 week upon enrolment: a control group (no additional risk information), and three intervention groups (genetic, imaging-based and genetic + imaging-based risk information). The goal is to randomize around 12,000 participants in phase 2 (~3,000 per trial arm). All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The remaining 18,000 participants who won't proceed to phase 2 will still be involved in the study and contacted through a phone call follow-up with specialist at the 5◦ and 10◦ year.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Ancona, 이탈리아
- 모병
- Irccs Inrca
-
연락하다:
- Roberto Antonicelli, MD
- 전화번호: +390718003450
- 이메일: r.antonicelli@inrca.it
-
Genova, 이탈리아
- 아직 모집하지 않음
- IRCCS San Martino
-
연락하다:
- Pietro Ameri, MD
- 이메일: pietro.ameri@unige.it
-
Milan, 이탈리아
- 모병
- IRCCS Ospedale San Raffaele
-
연락하다:
- Paolo Camici, MD
- 전화번호: 02 2643 8190/8191
- 이메일: cvriskit@hsr.it
-
Milan, 이탈리아
- 모병
- IRCCS Auxologico Italiano
-
연락하다:
- Gianfranco Parati, MD
- 전화번호: 02-61911.1
- 이메일: gianfranco.parati@unimib.it
-
Milan, 이탈리아
- 모병
- IRCCS Cardiologico Monzino
-
연락하다:
- Damiano Baldassarre, MD
- 전화번호: +39 02.58002369
- 이메일: damiano.baldassarre@cardiologicomonzino.it
-
Milan, 이탈리아
- 아직 모집하지 않음
- IRCCS Fondazione Cà Granda- Policlinico Milano
-
연락하다:
- Stefano Carugo, MD
- 이메일: stefano.carugo@policlinico.mi.it
-
Milan, 이탈리아
- 아직 모집하지 않음
- IRCCS Istituto Clinico Humanitas
-
연락하다:
- Giuseppe Ferrante, MD
- 이메일: giuseppe.ferrante@hunimed.eu
-
Milan, 이탈리아
- 모병
- IRCCS Mario Negri
-
연락하다:
- Maria Carla Roncaglioni, MD
- 전화번호: 0239014-501
- 이메일: cvrisk-it_fase1@marionegri.it
-
Milan, 이탈리아
- 모병
- IRCCS Multimedica
-
연락하다:
- Francesco Bandera, MD
- 전화번호: 02.242091
- 이메일: francesco.bandera@multimedica.it
-
Naples, 이탈리아
- 아직 모집하지 않음
- Irccs Synlab Sdn
-
연락하다:
- Carlo Cavaliere, MD
- 이메일: carlo.cavaliere@synlab.it
-
Palermo, 이탈리아
- 아직 모집하지 않음
- Irccs Ismett
-
연락하다:
- Manlio Cipriani, MD
- 이메일: mcipriani@ismett.edu
-
Pavia, 이탈리아
- 아직 모집하지 않음
- IRCCS Istituti Clinici Scientifici Maugeri
-
연락하다:
- Maria Teresa La Rovere, MD
- 이메일: mariateresa.larovere@icsmaugeri.it
-
Pavia, 이탈리아
- 아직 모집하지 않음
- IRCCS Fondazione Policlinico San Matteo
-
연락하다:
- Eloisa Arbustini, MD
- 이메일: e.arbustini@smatteo.pv.it
-
Pozzilli, 이탈리아
- 아직 모집하지 않음
- IRCCS Neuromed
-
연락하다:
- Maria Benedetta Donati, MD
- 이메일: mariabenedetta.donati@neuromed.it
-
Rome, 이탈리아
- 아직 모집하지 않음
- IRCCS Fondazione Policlinico Gemelli
-
연락하다:
- Giovanna Liuzzo, MD
- 이메일: giovanna.liuzzo@policlinicogemelli.it
-
Rome, 이탈리아
- 아직 모집하지 않음
- IRCCS San Raffaele Roma
-
연락하다:
- Massimo Volpe, MD
- 이메일: massimo.volpe@sanraffaele.it
-
San Donato Milanese, 이탈리아
- 모병
- IRCCS Policlinico San Donato
-
연락하다:
- Chiara Barberio, PhD
- 전화번호: 02-52774838
- 이메일: cvriskit@grupposandonato.it
-
연락하다:
- Ambra Cerri, PhD
-
수석 연구원:
- Lorenzo Menicanti, MD
-
부수사관:
- Emanuele Diangelantonio, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age: 40-80 years
- Apparently healthy individuals without previous medical history of CVD or diabetes (based on medical diagnosis)
- Participant recruitment arranged only at selected IRCCS (and associated Spokes) as part of the 'Rete Cardiologica'
- Participants must have signed the Informed Consent and Data Privacy Treatment forms
- Participants must have a personal e-mail address and internet connection
Exclusion Criteria:
- Age ≤40 or ≥80 years
- Individuals have previous medical history related to CVD (e.g., heart failure, congenital heart disorder, coronary heart disease) based on medical diagnosis
- Candidates have previously participated in clinical studies of 'Rete Cardiologica' (e.g., PREVITAL)
- Medical diagnosis of mental disorders
- Pregnancy based on self-reported information
- Previous history of type 1 or type 2 diabetes (based on medical diagnosis)
- Oncology patients (based on physician indication)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Control
No additional cardiovascular risk information/recommendation is provided to the subject other than SCORE2/SCORE2-OP results of phase I. Thereby, the control group does not undergo neither imaging nor genetic analysis. |
|
|
실험적: Imaging
Subjects randomized in the imaging arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on imaging data analysis (i.e., carotid ultrasound or calcium score) |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
|
실험적: Polygenic Risk Score (PRS)
Subjects randomized in this arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on polygenic risk score (PRS) analysis obtained from blood samples collected at the baseline visit |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
|
실험적: Imaging and Polygenic Risk Score (PRS)
Subjects randomized in this arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on both imaging data (e.g., carotid ultrasound and/or calcium score) and genetic analysis (e.g., PRS). |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in CVD risk using SCORE2/SCORE2-OP
기간: 12 months
|
The primary short-term outcome (i.e., 12 months after communication of the newly estimated CVD risk, following the randomisation step) is the change in CVD risk measured using SCORE2/SCORE2-OP risk prediction models. The CVD risk categories used to classify healthy people according to these scores are: 1) Low-to-moderate CVD risk: <50 years = <2.5 %; 50-69 years = <5%; ≥ 70 years = <7.5%. High CVD risk: <50 years = 2.5 to <7.5%; 50-69 years = 5 to <10%; ≥ 70 years 7.5 to <15%; Very high CVD risk: <50 years = ≥7.5%; 50-69 years = ≥10%; ≥ 70 years = ≥ 15%. |
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in cardiovascular modifiable risk factors
기간: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as cholesterol levels (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) (mg/dl) |
12 months
|
|
Change in cardiovascular modifiable risk factors
기간: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as blood pressure which will be measured 3 times in a row, and its average calculated (mmHg) |
12 months
|
|
Change in cardiovascular modifiable risk factors
기간: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as smoking habits (e.g., switch from "usual smoker" to "not smoking anymore" categories) |
12 months
|
|
Change in CVD prevention-drugs prescription
기간: 12 months
|
Secondary short-term outcomes will include changes in CVD prevention-drugs prescription with respect to the baseline visit |
12 months
|
|
Evaluation of participant's adherence to ESC recommendations
기간: 12 months
|
By means of validated questionnaires, the assessment of participants' adherence to the lifestyle and dietary guidelines of the European Society of Cardiology (ESC) will be performed. If and where applicable, drugs prescription adherence will be evaluated as well as psychological outcomes |
12 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
CVD events recording in long-term period
기간: 5-10 years
|
The long-term outcomes will include the registration of CVD events in all enrolled participants in the long-term period (e.g., non-fatal myocardial infarction, acute coronary syndrome, percutaneous transluminal coronary angioplasty (PTCA), Coronary artery bypass grafting (CABG), non-fatal stroke), CVD mortality, and total mortality |
5-10 years
|
공동 작업자 및 조사자
협력자
간행물 및 유용한 링크
일반 간행물
- Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D, de Benito Rubio V, Ignatiuk B, Raisi-Estabragh Z, Pawlak A, Karagiannidis E, Treskes R, Gaita D, Beltrame JF, McConnachie A, Bardinet I, Graham I, Flather M, Elliott P, Mossialos EA, Weidinger F, Achenbach S; Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022 Feb 22;43(8):716-799. doi: 10.1093/eurheartj/ehab892.
- Di Angelantonio E, Piepoli M, Castelvecchio S, Barberio C, Chiarello C, Cerri A, Boveri S, Cardani R, Ambrogi F, Guelfi S, Baldassarre D, Colombo G, Amato M, Baetta R, Arbustini E, Liuzzo G, Kaptoge S, Severino A, Ferrante G, La Rovere MT, Parati G, Pengo MF, Latini R, Roncaglioni MC, Rigoni M, De Curtis A, Frati L, Ameri P, Camici PG, Volpe M, Menicanti L. Integrating genetic and imaging information to enhance cardiovascular risk stratification: rationale and design of the CVRISK-IT randomised controlled trial. Eur Heart J Qual Care Clin Outcomes. 2026 Mar 4:qcag032. doi: 10.1093/ehjqcco/qcag032. Online ahead of print.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .